- Home
- SLND vs ADVM Comparison
SLND vs ADVM Comparison
Compare SLND & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- ADVM
- Stock Information
- Founded
- SLND 1900
- ADVM 2006
- Country
- SLND United States
- ADVM United States
- Employees
- SLND N/A
- ADVM N/A
- Industry
- SLND Military/Government/Technical
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLND Industrials
- ADVM Health Care
- Exchange
- SLND Nasdaq
- ADVM Nasdaq
- Market Cap
- SLND 160.7M
- ADVM 161.4M
- IPO Year
- SLND N/A
- ADVM 2014
- Fundamental
- Price
- SLND $3.05
- ADVM $5.75
- Analyst Decision
- SLND Buy
- ADVM Strong Buy
- Analyst Count
- SLND 2
- ADVM 6
- Target Price
- SLND $5.50
- ADVM $27.83
- AVG Volume (30 Days)
- SLND 100.0K
- ADVM 223.9K
- Earning Date
- SLND 11-12-2024
- ADVM 11-04-2024
- Dividend Yield
- SLND N/A
- ADVM N/A
- EPS Growth
- SLND N/A
- ADVM N/A
- EPS
- SLND N/A
- ADVM N/A
- Revenue
- SLND $1,029,117,999.00
- ADVM $1,000,000.00
- Revenue This Year
- SLND $0.91
- ADVM N/A
- Revenue Next Year
- SLND $5.38
- ADVM $1,294.35
- P/E Ratio
- SLND N/A
- ADVM N/A
- Revenue Growth
- SLND N/A
- ADVM N/A
- 52 Week Low
- SLND $1.85
- ADVM $5.82
- 52 Week High
- SLND $6.16
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- SLND 46.59
- ADVM 24.35
- Support Level
- SLND $2.83
- ADVM $6.81
- Resistance Level
- SLND $3.00
- ADVM $7.73
- Average True Range (ATR)
- SLND 0.36
- ADVM 0.46
- MACD
- SLND 0.03
- ADVM -0.23
- Stochastic Oscillator
- SLND 64.16
- ADVM 2.02
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.